RxSight (NASDAQ:RXST) Posts Earnings Results, Beats Estimates By $0.04 EPS

RxSight (NASDAQ:RXST) posted its quarterly earnings results on Wednesday. The company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.04, Zacks reports. RxSight had a negative net margin of 36.80% and a negative return on equity of 17.20%. The business had revenue of $33.74 million during the quarter, compared to analyst estimates of $32.55 million.

Here are the key takeaways from RxSight’s conference call:

• Core product sales declined 19% year over year to $27.2 million, while LAL unit volume fell 9% to 24,917 units amid competitive trialing and broader market headwinds. Gross margin excluding Alcon also decreased to 71.2% from 74.9%, primarily due to higher inventory-related costs.
• Management withdrew its full-year 2026 financial guidance, citing the need for a thorough assessment and flexibility to make potential strategic or operational changes. Formal guidance is expected to resume with the company’s fourth-quarter results in early 2027.
• The company reported a strategic collaboration with Alcon that contributed $6.5 million of second-quarter revenue and is expected to generate $30 million to $40 million in 2026 revenue, plus future milestones and royalties. RxSight ended the quarter with approximately $209 million in cash and investments, before receiving an additional $60 million upfront payment after quarter-end.
• New CEO Aziz Mottiwala plans to shift the commercial strategy from establishing broad account reach to driving deeper utilization within the existing 1,166-unit LDD installed base. The company intends to eventually double its U.S. sales team, primarily through internal resource reallocations, while improving practice workflows, physician education, and patient selection.
• Management said early third-quarter trends are encouraging, but expects continued competition, product trialing, seasonality, affordability pressures, and broader market conditions to affect results. Alcon-related revenue is expected to be limited in the third quarter, with most of the remaining 2026 contribution recognized in the fourth quarter.

RxSight Stock Up 3.3%

Shares of RXST traded up $0.20 during mid-day trading on Friday, hitting $6.28. 480,655 shares of the company’s stock were exchanged, compared to its average volume of 976,800. The stock has a market cap of $260.12 million, a price-to-earnings ratio of -5.54 and a beta of 1.13. The firm has a fifty day moving average of $5.29 and a two-hundred day moving average of $6.65. RxSight has a twelve month low of $4.48 and a twelve month high of $13.22.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on RXST shares. Bank of America cut their target price on shares of RxSight from $8.00 to $6.50 and set an “underperform” rating for the company in a research report on Tuesday, July 7th. Wells Fargo & Company dropped their price target on shares of RxSight from $11.00 to $9.00 and set an “equal weight” rating on the stock in a research note on Thursday, May 7th. Needham & Company LLC reiterated a “buy” rating and set a $11.00 price objective on shares of RxSight in a report on Tuesday, July 7th. Wall Street Zen raised RxSight from a “strong sell” rating to a “sell” rating in a research report on Sunday, July 12th. Finally, Weiss Ratings downgraded RxSight from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, June 11th. Two research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Reduce” and an average target price of $8.59.

Institutional Trading of RxSight

Several large investors have recently made changes to their positions in the stock. Raymond James Financial Inc. bought a new position in shares of RxSight in the second quarter valued at approximately $28,000. Caitong International Asset Management Co. Ltd raised its stake in shares of RxSight by 440.7% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,758 shares of the company’s stock valued at $39,000 after purchasing an additional 3,063 shares in the last quarter. Larson Financial Group LLC lifted its holdings in shares of RxSight by 110.5% during the 3rd quarter. Larson Financial Group LLC now owns 3,979 shares of the company’s stock worth $36,000 after acquiring an additional 2,089 shares during the period. Tower Research Capital LLC TRC boosted its holdings in RxSight by 156.2% during the second quarter. Tower Research Capital LLC TRC now owns 5,574 shares of the company’s stock valued at $72,000 after purchasing an additional 3,398 shares in the last quarter. Finally, Russell Investments Group Ltd. boosted its stake in RxSight by 112.3% in the 2nd quarter. Russell Investments Group Ltd. now owns 8,684 shares of the company’s stock valued at $113,000 after buying an additional 4,593 shares in the last quarter. Institutional investors own 78.78% of the company’s stock.

About RxSight

RxSight, Inc is a medical technology company focused on the development and commercialization of advanced intraocular lens (IOL) systems for patients undergoing cataract surgery and lens replacement procedures. The company’s flagship product, the Light Adjustable Lens (LAL), is designed to provide customized vision correction by allowing non?invasive post?operative adjustments. Using ultraviolet light, surgeons can fine?tune the lens power after implantation to achieve optimal visual outcomes, reducing reliance on glasses or contact lenses and enhancing patient satisfaction.

Founded in 2011 and headquartered in Aliso Viejo, California, RxSight has pursued regulatory clearances and market access across multiple regions.